Prognostic value of c-erbB-2 expression in papillary thyroid carcinoma

NuklearMedizin

Volumn 44, Issue 5, 2005, Pages 179-184

  Freudenberg, Lutz S ^a   Sheu, S ^a   Gorges R ^a   Mann, K ^a   Bokler, S ^a   Frilling, A ^a   Schmid, K W ^a   Bockisch, A ^a   Otterbach, F ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

c erbB 2; Her 2 neu; Oncogene; Papillary thyroid cancer; Recurrence

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE F 18; IODINE 131; ONCOPROTEIN; PARAFFIN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; ECHOGRAPHY; EVALUATION; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOCYTOCHEMISTRY; INTENSITY MODULATED RADIATION THERAPY; MALE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; QUANTITATIVE ANALYSIS; SCHOOL CHILD; THYROID PAPILLARY CARCINOMA; TUMOR CELL; TUMOR RECURRENCE; WHOLE BODY RADIATION;

EID: 27644475925     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1625202     Document Type: Article

References (44)

1. Aasland R, Lillehaug JR, Male R et al. Expression of oncogenes in thyroid tumours: Coexpression of c-erbB-2/neu and c-erbB. Br J Cancer 1988; 57: 358-63.
2. Adam L, Vadlamudi R, Kondapaka S et al. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinostol-3 kinase. J Biol Chem 1998; 273: 28238-46.
3. Akslen LA, Varhaug JE. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival. Cancer 1995; 76: 1643-54.
4. Auguste LJ, Masood S, Westerband A et al. Oncogene expression in follicular neoplasms of the thyroid. Am J Surg 1992; 164: 592-3.
5. Bieche I, Franc B, Vidaud D et al. Analyses of MYC, ERBB2, and CCND1 genes in benign and malignant thyroid follicular cell tumors by real-time polymerase chain reaction. Thyroid 2001; 11: 147-52.
6. Chen L, Zhang W, Fregien N et al. The Her-2/neu oncogene stimulates the transcription of N-acetyl-glucosaminyltransferase V and expression of its cell surface oligosaccharide products. Oncogene 1998; 17: 2087-93.
7. Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall 1984.
8. De Potter CR, van Daele S, van de Vijver MJ et al. The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues. Histopathology 1989; 15: 351-62.
9. D'Emilia J, Bulovas K, D'Ercole K et al. Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon. Oncogene 1989; 4: 1233-9.
10. Dietlein M, Dressler J, Farahati J et al. Verfahrens-anweisung zur Radioiodtherapie (RIT) beim differenzierten Schilddrüsenkarzinom (Version 2). Nuklearmedizin 2004; 43: 115-20.
11. Dietlein M, Dressler J, Grünwald F et al. Leitlinie zur Schilddrüsendiagnostik (Version 2). Nuklearmedizin 2003; 42: 109-15.
12. Drebin JA, Link VC, Stern DF et al. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 1985; 41: 697-706.
13. Duh QY, Gum ET, Gerend PL et al. Epidermal growth factor receptors in normal and neoplastic thyroid tissue. Surgery 1985; 98: 1000-7.
14. Fagin JA, Matsuo K, Karmaker A. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993; 91: 179-84.
15. th ed. American Joint Committee on Cancer. Philadelphia, Pa: Lippincott-Raven 1997.
16. Frilling A, Görges R, Tecklenborg K et al. Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma. Surgery 2000; 128: 1067-74.
17. Gebhardt F, Zaenker K, Brandt B. Differential expression of alternatively spliced c-erbB-2 mRNA in primary tumors, lymph node metastases, and bone marrow micro metastases from breast cancer patients. Biochem Biophys Res Commun 1998; 247: 319-23.
18. Hall PA, Hughes CM, Staddon SL et al. The c-erbB-2 protooncogene in pancreatic cancer. J. Pathol 1990; 161: 195-200.
19. Hancock MC, Langton BC, Chan T et al. A monoclonal antibody against the C-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 1991; 51: 4575-80.
20. Haugen DR, Akslen LA, Varhaug JE et al. Demonstration of a TGF-alpha-EGF-receptor autocrine loop and c-myc protein over-expression in papillary thyroid carcinomas. Int J Cancer 1993; 55: 37-43.
21. Haugen DR, Akslen LA, Varhaug JE et al. Expression of c-erbB-2 protein in papillary thyroid carcinomas. Br J Cancer 1992; 65: 832-7.
22. Haugen DR, Akslen LA, Varhaug JE et al. Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. Cancer Res 1996; 56: 1184-8.
23. Hynes NE, Stern DF. The biology of erbB-2/neu/ HER-2 and its role in cancer. Biochim Biophys Acta 1994; 1198: 165-84.
24. Kraus MH, Issing W, Miki T et al. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 1989; 86: 9193-7.
25. Lemoine NK, Wyllie FS, Lillehaug JR et al. Absence of abnormalities of the c-erbB-1 and c-erbB-2 proto-oncogenes in human thyroid neoplasia. Eur J Cancer 1990; 26: 777-9.
26. Martin-Lacave I, Utrilla JC. Expression of a neu/ c-erbB-2-like product in neuroendocrine cells of mammals. Histol Histopathol 2000; 15: 1027-33.
27. Mazzucchelli L, Burckhardt E, Hirsiger H et al. Interphase cytogenetics in oncocytic adenomas and carcinomas of the thyroid gland. Hum Pathol 2000; 31: 854-9.
28. Pegram MD, Finn RS, Arzoo K et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cells. Oncogene 1997; 15: 537-47.
29. Perkins AS, Vande Wonde GF. Principle of molecular cell biology of cancer oncogenes. In: Devita VT, Hellman CS, Rosenberg SA (eds). Cancer principles and practice of oncology. Philadelphia: Lippincott 1993.
30. Plowman GD, Culouscou JM, Whitney GS et al. Ligand-specific activation of HER4/p180erbB4 et al. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 1993; 90: 1746-59.
31. Shih C, Padhy LC, Murray M et al. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 1981; 290: 261-4.
32. Siperstein AE, Zeng QH, Gum ET et al. Adenylate cyclase activity as a predictor of thyroid tumor aggressiveness. World J Surg 1988; 12: 528-33.
33. Sirvent JJ, Santafe M, Salvado MT et al. Hormonal receptors, cell proliferation fraction (ki-67) and c-erbB-2 amplification in breast cancer. Relationship between differentiation degree and axillary lymph node metastasis. Histol Histopathol 1994; 9: 563-70.
34. Slamon DJ, Godolphin W, Jones LA et al. Studies of the c-erbB-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
35. Soares P, Sambade C, Sobrinho-Simoes MA. Expression of c-erbB-2 in tumours and tumour-like lesions of the thyroid. Int J Cancer 1994; 56: 459-61.
36. Soda G, Antonaci A, Bosco D et al. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas. J Exp Clin Cancer Res 1999; 18: 363-7.
37. Stancovski I, Hurwitz E, Leitner O et al. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci U S A 1991; 88: 8691-5.
38. Sugg SL, Ezzat S, Zheng L et al. Cytoplasmic staining of erbB-2 but not mRNA levels correlates with differentiation in human thyroid neoplasia. Clin Endocrinol (Oxf) 1998; 49: 629-37.
39. Sundaresan S, Roberts PE, King KL et al. Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression. Endocrinology 1998; 139: 4756-64.
40. Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 1997; 57: 1199-205.
41. Utrilla JC, Martin-Lacave I, San Martin MV et al. Expression of c-erbB-2 oncoprotein in human thyroid tumours. Histopathology 1999; 34: 60-5.
42. Wieler H, Bartenstein P, Becker HP et al. Leitlinie zur Therapie maligner Schilddrüsentumoren: Plädoyer für die Aktualisierung. Nuklearmedizin 2004; 43: 121-3.
43. Yokota J, Yamamoto T, Toyoshima K et al. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1986; 5: 765-7.
44. Zoll B, Kynast B, Corell B et al. Alterations of the c-erbB-2 gene in human breast cancer. J Cancer Res Clin Oncol 1992; 118: 468-73.